X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Novartis’ take on what to expect as tech transforms healthcare

Content Team by Content Team
13th March 2018
in Americas, News

He is a medical doctor by training but it is big data and its implications that is engaging his attention and with good reason. Dr Shreeram Aradhye, chief medical officer at Novartis Pharma, USA, says, “we will need to focus on true breakthroughs, therapies that are truly transformative – either life enhancing or meaningfully life changing – He was speaking at BioAsia 2018 in Hyderabad on Friday, February 23rd.

He talked about therapies that can become as personalized as possible and on how Novartis was keen on these and pursuing scientific innovation. He saw value in the principle of understanding pathways, and said “that understanding of science can be benefited by the use of technology and big data that allows us to do things more efficiently.” On breakthroughs, he said, “what we produce are no longer just chemical or biological drugs but we can actually use modified human cells as drugs (especially in dealing with cancer care).

Also, he said, “for the first time, through the use of technology we now have the ability to understand people living with conditions in a more holistic manner, in what I call, a quantified life, in which the availability of big data is making it possible to get more “real world data” – data collected from outside the trial construct (where number of things are highly controlled). Here, the information is from the real world – could be for instance, from simple wearable devices people wear. All of which to help find patterns that may have not been possible earlier.

Later, Business Today asked him on where does India fit into this and he said: “Our development centre here in Hyderabad is like our sites in New Jersey or Basel and we think of it as an integral part of our global organisation. Many parts of the work that we do for drug development world wide, are being done by colleagues in Hyderabad and they are fundamental part of the journey.”

What about the common gripe that the regulatory regime in India is not conducive for clinical trials. How does Novartis therefore ensure that Indian population does not go under represented in the trials for new drugs? “In programmes where we want Indian representation, we are able to get it. We have the infrastructure and the team to do it. In general, I believe we have the necessary infrastructure and the support needed to be able to do the kind of trials we expect to do and in fact, India for us is always considered as a core component of our global programmes,” he said.

On plans to expand the operations in India, he said: “That depends on how things evolve but I think we have a significant presence already with around 4,000 people here in Hyderabad.”

Previous Post

Pfizer encourages public to view and listen webcast of its presentation at Healthcare conference

Next Post

EMA Advises Recall of AbbVie, Biogen MS Drug

Related Posts

Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Next Post
EMA Advises Recall of AbbVie, Biogen MS Drug

EMA Advises Recall of AbbVie, Biogen MS Drug

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In